NASDAQ · Drug Manufacturers - Specialty & Generic

AKAN (AKAN) Stock

$5.31 -16.90% NASDAQ: AKAN Healthcare

Valuation

MetricValue
Price$5.31
Market Cap$171863
P/E Ratio-0.06
P/B Ratio0.12
P/S Ratio1.31
EPS (TTM)$-257.60
52-Week High$209.23
52-Week Low$2.30
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-100.00%
ROA-50.00%
ROCE-100.00%
Gross Margin-400.00%
Operating Margin-400.00%
Net Margin-6.20%
Debt/Equity0.12
Current Ratio1.25

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$3.0M$2.0M$1.0M
Operating Profit$-2.0M$-3.0M$-20.0M$-10.0M$-4.0M
Net Profit$-2.0M$-8.0M$-12.0M$-32.0M$-4.0M
EPS$-3980.00$-14066.48$-16828.00$-2865532.00$-257.60
Op Margin-80787.3%-6203.4%-770.2%-465.3%-523.8%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$4.0M$8.0M$39.0M$9.0M$8.0M
Total Liabilities$9.0M$10.0M$12.0M$13.0M$4.0M
Cash$0$3.0M$0$0$4.0M
Borrowings$9.0M$10.0M$4.0M$4.0M$0

Latest News

Akanda Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement TMX Newsfile · Jun 18, 2026 Why Is AKAN Stock Surging Today? Stocktwits · Jun 12, 2026 Akanda Shares Surge After Restoring Nasdaq Compliance (AKAN) InvestorsHub · Jun 12, 2026 Akanda Corp. Regains Compliance with Nasdaq Periodic Filing Requirement TMX Newsfile · Jun 12, 2026 Top Midday Decliners MT Newswires · May 26, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-1.0M$-7.0M$-11.0M$-2.0M$-4.0M
Investing Cash Flow$-1.0M$-1.0M$-5.0M$0$-3.0M
Financing Cash Flow$0$0$0$2.0M$-1.0M
Net Cash Flow$-1.0M$3.0M$-3.0M$0$4.0M
Free Cash Flow$-2.0M$-7.0M$-12.0M$-2.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-536.22%
Quick Ratio1.25
Interest Coverage—
Return 1Y-88.99%
Return 3Y-99.73%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BBLG $1.02 -4.21% -1.10 $1.84M 0.00%
GCTKGlucoTrack, Inc. $0.29 +0.03% -0.05 $165300 0.00%
GNPX $5.99 -1.16% -0.03 $3.02M 0.00%
HSCS $2.18 +4.81% -0.70 $4.71M 0.00%
IMCC $0.12 +0.26% -1062.50 $357295 0.00%

About AKAN

AKAN is led by CEO Katharyn Field, employs 46 people, headquartered in GB, publicly traded since 2022.

AKAN stock trades at $5.31 with a market capitalization of $171863. The stock is valued at a price-to-earnings (P/E) ratio of -0.06, price-to-book of 0.12, price-to-sales of 1.31. Over the past 52 weeks the stock has ranged between $2.30 and $209.23, and currently trades 97.5% below its 52-week high.

On profitability, AKAN generates a return on equity (ROE) of -100.00%, return on capital employed of -100.00%, an operating margin of -400.00%, a net profit margin of -6.20%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides